Key Segmentation
By Type of Data
-
Clinical Data
-
Claims and Billing Data
-
Pharmaceutical and R&D Data
-
Genomic and Molecular Data
-
Behavioral and Patient-Reported Data
-
Others
By Application
-
Clinical Research and Trials
-
Drug Discovery and Development
-
Population Health Management
-
AI and ML Model Training
-
Value-Based Care and Quality Improvement
-
Others
By End-User
-
Pharmaceutical Companies
-
Healthcare Providers
-
Health Insurance and Payers
-
Biotechnology Firms
-
Academic and Research Institutions
-
Government and Regulatory Agencies
-
Others
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
North America dominated the market with approximately 39.7% of global revenues in 2025, led by the United States with the world's most extensive EHR infrastructure, HIPAA's established de-identification frameworks, and the concentration of pharmaceutical, biotechnology, and health technology companies whose demand for real-world evidence and AI training data drives market leadership.
Clinical Data dominated with approximately 20.6% of revenues in 2025, driven by the widespread adoption of certified EHR systems across hospitals and primary care practices, the fundamental centrality of structured clinical records for research and AI model training, and the broad range of pharmaceutical, population health, and precision medicine applications that clinical datasets serve.
The exponential demand for large-scale, privacy-compliant health datasets to train healthcare AI models, combined with the expanding FDA and EMA regulatory acceptance of real-world evidence derived from de-identified health data in drug approval submissions, and the universal healthcare transition toward value-based care models requiring population-scale longitudinal data analytics.
The De-identified Health Data Market was valued at USD 8.527 billion in 2025.
The De-identified Health Data Market is expected to grow at a CAGR of 9.32% from 2026 to 2035.
Get in Touch
